Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

New strategy for monitoring targeted therapy: molecular imaging

Authors Teng FF, Meng X, Sun XD, Yu JM

Received 9 July 2013

Accepted for publication 8 August 2013

Published 30 September 2013 Volume 2013:8(1) Pages 3703—3713

DOI https://doi.org/10.2147/IJN.S51264

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Fei-Fei Teng, Xue Meng, Xin-Dong Sun, Jin-Ming Yu

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, People's Republic of China

Abstract: Targeted therapy is becoming an increasingly important component in the treatment of cancer. How to accurately monitor targeted therapy has been crucial in clinical practice. The traditional approach to monitor treatment through imaging has relied on assessing the change of tumor size by refined World Health Organization criteria, or more recently, by the Response Evaluation Criteria in Solid Tumors. However, these criteria, which are based on the change of tumor size, show some limitations for evaluating targeted therapy. Currently, genetic alterations are identified with prognostic as well as predictive potential concerning the use of molecularly targeted drugs. Conversely, considering the limitations of invasiveness and the issue of expression heterogeneity, molecular imaging is better able to assay in vivo biologic processes noninvasively and quantitatively, and has been a particularly attractive tool for monitoring treatment in clinical cancer practice. This review focuses on the applications of different kinds of molecular imaging including positron emission tomography-, magnetic resonance imaging-, ultrasonography-, and computed tomography-based imaging strategies on monitoring targeted therapy. In addition, the key challenges of molecular imaging are addressed to successfully translate these promising techniques in the future.

Keywords: molecular imaging, targeted therapy, PET, MRI, US, CT

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Validation of the custo screen 400 ambulatory blood pressure-monitoring device according to the European Society of Hypertension International Protocol revision 2010

Bramlage P, Deutsch C, Krüger R, Wolf A, Müller P, Zwingers T, Beime B, Mengden T

Vascular Health and Risk Management 2014, 10:303-309

Published Date: 13 May 2014

Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin

Zhang KC, Lv SW, Li XY, Feng YF, Li X, Liu L, Li S, Li YJ

International Journal of Nanomedicine 2013, 8:3227-3239

Published Date: 22 August 2013

Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138–  CD34– tumor stem-like cells in multiple myeloma-bearing mice

Yang C, Wang J, Chen D, Chen J, Xiong F, Zhang H, Zhang Y, Gu N, Dou J

International Journal of Nanomedicine 2013, 8:1439-1449

Published Date: 12 April 2013

Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?

Mahabala C, Kamath P, Bhaskaran U, Pai ND, Pai AU

Vascular Health and Risk Management 2013, 9:125-133

Published Date: 24 March 2013

Simultaneous, noninvasive, and transdermal extraction of urea and homocysteine by reverse iontophoresis

Congo Tak-Shing Ching, Tzong-Ru Chou, Tai-Ping Sun, et al

International Journal of Nanomedicine 2011, 6:417-423

Published Date: 20 February 2011